Hypoxia-Directed Treatment of Human Papillomavirus–Related Oropharyngeal Carcinoma
Lee N, Sherman E, Schöder H, Wray R, Boyle J, Singh B, Grkovski M, Paudyal R, Cunningham L, Zhang Z, Hatzoglou V, Katabi N, Diplas B, Han J, Imber B, Pham K, Yu Y, Zakeri K, McBride S, Kang J, Tsai C, Chen L, Gelblum D, Shah J, Ganly I, Cohen M, Cracchiolo J, Morris L, Dunn L, Michel L, Fetten J, Kripani A, Pfister D, Ho A, Shukla-Dave A, Humm J, Powell S, Li B, Reis-Filho J, Diaz L, Wong R, Riaz N. Hypoxia-Directed Treatment of Human Papillomavirus–Related Oropharyngeal Carcinoma. Journal Of Clinical Oncology 2024, 42: 940-950. PMID: 38241600, PMCID: PMC10927322, DOI: 10.1200/jco.23.01308.Peer-Reviewed Original ResearchConceptsProgression-free survivalCurative-intent chemoradiotherapyLocoregional controlOropharyngeal carcinomaOverall survivalGrade 3Adverse eventsTumor hypoxiaHuman papillomavirus (HPV)-related oropharyngeal carcinomasHPV-related oropharyngeal carcinomaMedian follow-up timeHypoxic tumorsSurgical removal of diseaseAcute grade 3Late grade 3HPV-related carcinomasPhase II studyFollow-up timeMeasure tumor hypoxiaRemoval of diseaseDefinitive chemoradiotherapyStandard chemoradiotherapyGross diseaseLate dysphagiaOS rates
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply